Jaguar Health (JAGX) Lytham Partners Fall 2025 Investor Conference summary

Key catalysts and inflection points

• Recent and upcoming catalysts include FDA meetings, orphan drug applications, and new clinical data releases for cancer therapy-related diarrhea and rare intestinal failure diseases.

• Crofelemer, a plant-based, FDA-approved drug, is unique for its exclusivity and safety profile, with no generic pathway and no serious adverse events reported.

• Statistically significant results were achieved in metastatic breast cancer patients, leading to an orphan drug application and plans for a supplemental NDA after a treatment trial expected to complete in 2026.

• Expanded access programs and digital patient advocacy initiatives are underway to address unmet needs in cancer supportive care.

• Business development efforts focus on non-dilutive partnerships, leveraging de-risked programs and recent orphan designation to attract larger deals.

Clinical development and market opportunities

• Four phase 2 studies are ongoing in rare intestinal failure diseases, with groundbreaking reductions in parenteral nutrition for MVID and short bowel syndrome pediatric patients.

• Orphan designations in the US and Europe for both short bowel syndrome and MVID support regulatory and reimbursement strategies.

• Market research estimates the short bowel syndrome market at $4.5 billion, highlighting blockbuster potential.

• Crofelemer’s mechanism normalizes gut function without systemic absorption or opioid-related risks, making it suitable for complex patient populations.

• Confirmatory trials and upcoming data presentations are expected to further validate efficacy and support expedited approvals.

Commercialization and cross-species insights

• Mytesi sales in the HIV market are growing at about 5% annually, providing valuable commercialization experience and patient access infrastructure.

• Crofelemer is conditionally approved for chemotherapy-induced diarrhea in dogs, with ongoing confirmatory trials and a recent $250,000 grant award.

• Insights from the veterinary market, including manufacturer support, are informing human oncology commercialization strategies.

• The company is prioritizing non-dilutive funding and strategic partnerships to advance both human and animal health programs.

• The focus remains on expanding indications, improving patient quality of life, and accelerating access to innovative therapies.